www.thelancet.com/lancetgh Vol 7 April 2019

Severe mental illness and substance use disorders in prisoners in low-income and middle-income countries: a systematic review and meta-analysis of prevalence studies

Gergő Baranyi, Carolin Scholl, Seena Fazel, Vikram Patel, Stefan Priebe, Adrian P Mundt

Summary

Background Although more than two thirds of the world's incarcerated individuals are based in low-income and middle-income countries (LMICs), the burden of psychiatric disorders in this population is not known. This review provides estimates for the prevalence of severe mental illness and substance use disorders in incarcerated individuals in LMICs.

Methods For this systematic review and meta-analysis, we searched 17 electronic databases to identify prevalence studies of psychiatric disorders in prison populations in LMICs, published between January, 1987, and May, 2018. We included representative studies from general prison samples, providing information about four major psychiatric diagnoses: psychosis, major depression, alcohol use disorders, and drug use disorders. We pooled data from studies using random-effects meta-analyses and assessed the sources of heterogeneity by meta-regression. We extracted general population estimates from the Global Burden of Diseases 2016 database to calculate comparative prevalence ratios. This study is registered with PROSPERO, number CRD42015020905.

Findings We identified 23 publications reporting prevalence estimates of severe mental illness and substance use disorders for 14527 prisoners from 13 LMICs. In this population, the estimated pooled 1 year prevalence rates for psychosis were $6 \cdot 2\%$ (95% CI $4 \cdot 0 - 8 \cdot 6$), $16 \cdot 0\%$ ($11 \cdot 7 - 20 \cdot 8$) for major depression, $3 \cdot 8\%$ ($1 \cdot 2 - 7 \cdot 6$) for alcohol use disorders, and $5 \cdot 1\%$ ($2 \cdot 9 - 7 \cdot 8$) for drug use disorders. We noted increased prevalence at prison intake and geographic variations for substance use disorders. For alcohol use disorders, prevalence was higher in the southeast Asian region than in the eastern Mediterranean region; and drug use disorders were more prevalent in the eastern Mediterranean region than in Europe. Prevalence ratios indicated substantially higher rates of severe mental illness and substance use disorders among prisoners than in the general population (the prevalence of non-affective psychosis was on average 16 times higher, major depression and illicit drug use disorder prevalence were both six times higher, and prevalence of alcohol use disorders was double that of the general population).

Interpretation The prevalence of major psychiatric disorders is high in prisoners in LMIC compared with general populations. As these findings are likely to reflect unmet needs, the development of scalable interventions should be a public health priority in resource-poor settings.

Funding CONICYT of the Chilean government and the Wellcome Trust.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction

More than 7 million prisoners are based in low-income and middle-income countries (LMICs), comprising about 70% of the world's total prison population.¹ Conditions in these facilities are usually characterised by overcrowding, poor nutrition, and sanitation, and limited or complete lack of access to basic health care, which have raised public health and human rights concerns.^{2,3} However, apart from one review in 2012,⁴ which included only a few studies from LMICs, the prevalence of major psychiatric disorders is not reliably known.⁴⁵ Over the past 5 years, several high-quality prevalence studies have been published from LMIC settings.⁶⁷

Mental health and substance use disorders are common among people involved with the criminal justice system.^{48.9} Although prisoners with unmet mental health-care needs are at higher risk of suicide attemps,¹⁰ mortality,¹¹ and recidivism after release,¹² mental health disorders often remain undiagnosed and untreated in correctional settings.^{3,5} Up to now, most research on mental health problems in prisoners has focused on high-income countries (HICs). Establishing the prevalence rates of severe mental illness and substance use disorders in LMICs will provide a basis for service and policy developments in countries with resourcepoor correctional settings.

We aimed to systematically review the literature of severe mental illness (psychotic disorders and major depression) and substance use disorders (alcohol use disorders and illicit drug use disorders) in prison



Lancet Glob Health 2019; 7: e461–71

See Comment page e392

Centre for Research on **Environment** Society and Health, Department of Geography, School of GeoSciences. The University of Edinburgh, Edinburgh, UK (G Baranyi MPH); School of Informatics, The University of Edinburah, Edinburah, UK (C Scholl MSc); Department of Psychiatry, University of Oxford, Oxford, UK (S Fazel FRCPsych); Department of Global Health & Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA (V Patel PhD); Unit for Social and Community Psychiatry, WHO Collaborating **Centre for Mental Health** Services Development, Oueen Mary University of London, London, UK (S Priebe ERCPsych): Medical Faculty, Universidad Diego Portales, Santiago, Chile (A P Mundt PhD): and Medical School, Universidad San Sebastián, Puerto Montt, Chile (A P Mundt)

Correspondence to: Prof Adrian P Mundt, Medical Faculty, Universidad Diego Portales, 8370068 Santiago, Chile adrian.mundt@mail.udp.cl

Research in context

Evidence before this study

Although 70% of incarcerated men and women are residing in low-income and middle-income countries, almost all evidence on mental disorders among prisoners is based on studies from high-income countries, providing implications that are not applicable or generalisable to poorly resourced settings. The prevalence of psychiatric disorders in the penal justice systems of low-income and middle-income countries (LMICs) is likely to differ from high-income countries because of the scarcity of resources, as well as cultural and legal factors.

To fill this knowledge gap, we systematically searched for prison prevalence studies based in LMICs published between January, 1987, and May, 2018, in 17 electronic global databases, including sources of grey literature. Our search terms covered a range of key words and subject headings on mental health, prison conditions, and epidemiological investigations. We included representative studies from general prison samples from LMICs, providing information about four major psychiatric diagnoses: psychosis, major depression, alcohol use disorders, and drug use disorders, published in any language. Our search identified no systematic reviews focusing on the context of LMICs.

populations in LMICs, to estimate prevalence rates and prevalence ratios, and to examine sources of heterogeneity.

Methods

This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).¹³

Search strategy and selection criteria

We conducted a multistage search to identify relevant literature on the prevalence of severe mental illness and substance use disorders in prison populations from LMICs published between January, 1987, and May, 2018. The search strategy comprised a search of online databases (ASSIA; CAB Abstracts; CNKI; Criminal Justice Database; Embase; Global Health; IBSS; LILACS; MEDLINE; NCJRS; PAIS Index; PsycINFO; Scopus; Social Services Abstracts) and the grey literature (Google Scholar; Open Grey; ProQuest Dissertations and Theses Global); screening of reference lists of identified papers and relevant reviews; and corresponding with authors to gain additional information or to clarify data. The appendix provides a full list of the search terms used for the online database searches. Articles from all languages were included.

We included studies in which the following criteria were met: data were collected in general prison populations; the sample was representative for the population of the assessed correctional facility; the

Added value of this study

We identified 23 studies from 13 countries, most of which had not previously been included in reviews. Our analysis established the pooled 1 year prevalence rates of four major mental illnesses in prisoner populations in LMICs. Furthermore, our findings emphasise that on arrival to prisons in LMICs, mental disorders may be more prevalent than in samples that also represent later stages of imprisonment.

Implications of all the available evidence

In LMICs, the prevalence of psychiatric disorders in prison populations is higher than among people living in the community. Rates in prison populations of LMICs might be even higher than in high-income countries. Because correctional facilities often lack basic health care in low-income and middle-income economies, the implementation of cost-effective interventions and scalable treatments for individuals with mental health problems are needed. Since human rights violations, and physical and psychological abuse are more common in resource-poor correctional settings, protecting the rights and health of people with mental illnesses should be a priority for penal justice policies.

study was conducted in a LMIC at the time of data collection or maximum 1 year after classification has changed; the prevalence of severe mental illness and substance use disorders were based on clinical examinations or established with validated questionnaires as part of a clinical or research interview; and diagnoses met the criteria of international diagnostic classifications (Diagnostic and Statistical Manual of Mental Disorders [DSM] or International Classification of Diseases [ICD]). Studies were excluded when: prevalence rates were established in selected subgroups of incarcerated individuals (eg, offender type); sampling strategy was convenient;14 data originated from a HIC;15 prevalence was reported based on measures and tools that used solely self-report, which did not fulfil diagnostic criteria. Finally, conference abstracts and duplicates were excluded. Two researchers (GB and CS) screened abstracts and full-texts and disagreements between the reviewers were resolved by consensus with APM.

Data analysis

Two reviewers (GB and CS) independently extracted year and country of data collection, sex, age, type of recruitment (from all prisoners or at admission), sampling strategy, non-response rate, time served in prison, interviewer (mental health professional or research assistant), diagnostic classification system (DSM or ICD), diagnostic instrument, and number of incarcerated individuals, for which 1 year prevalence was

See Online for appendix

reported for psychotic illness (ICD-10 codes: F20-F29, F31, F32 · 3, F33 · 3) and major depression (F32-33, except F32·3, F33·3). We extracted both 1 year and lifetime prevalence rates of alcohol (F10) and drug use disorders (F11-19, except F17). Male and female samples were considered separately. Studies that did not report separate rates but included less than 10% of the study participants of one sex were included as representative for the other sex; otherwise they were described as mixed samples. When the year of data collection was not reported, we imputed a year based on the average mean difference between the year of publication and data collection derived from the other studies (4 years).9 We prespecified categories for sample size (n<500, $n \ge 500$) and average time served in prison (time <1 year, time \geq 1 year). Countries were categorised into LMIC and HIC based on their per capita Gross National Income, calculated with the World Bank's Atlas method for the year of data collection. To examine geographic variation of prevalence estimates within LMIC, we used WHO regional classification. If schizophrenia-spectrum, bipolar disorder (which can present with acute psychotic states), and psychotic depression were presented separately, we combined them, in order to create one estimate for overall psychotic disorders. By combining abuse and dependence disorders, we produced single rates for alcohol and drug use disorders.

To assess methodological quality, two reviewers (GB and CS) evaluated the internal and external validity of the included samples based on a modified scale of ten questions,¹⁶ which allowed a critical appraisal of prevalence rates in epidemiological investigations (appendix).

To account for the heterogeneity between studies, we performed random-effects meta-analysis by estimating the pooled mean of the distribution.¹⁷ For individual samples, we first calculated 95% score confidence intervals (CIs). Variance of the proportions was stabilised with Freeman-Tukey double arcsine transformation and pooled together with the DerSimonian and Laird method.¹⁸ The inconsistency between samples was quantified with *I*².¹⁹ As previous prevalence meta-analyses reported high between-sample heterogeneity, we also provided prevalence ranges.²⁰ Sensitivity analysis was conducted pooling 6 month estimates of severe mental illness as reported in a review for HIC.⁴ Pooled rates for subgroups were displayed, when at least five samples were present.

We conducted random-effects meta-regressions by assessing pre-specified sample characteristics on the pooled estimate.⁷⁷ Models in the meta-regression were fitted with the restricted maximum likelihood method and corrected with the Hartung-Knapp variance estimator.²¹ To test whether lower quality investigations systematically distort the pooled estimates, we included the quality score of samples as a covariate. Univariate meta-regression analysis was performed when at least ten samples were available,²² multivariate by 20 or more samples, retaining only significant variables (p<0.05).

We calculated prevalence ratios (PR) and their 95% CIs to quantify the difference between the prevalence among prisoners (p) in each sample and in the sex-matched general populations (P) of the respective countries based on the following equation²³:

$$\left(PR = \frac{p}{P}; SE = \sqrt{\frac{1}{p \times n} + \frac{1}{P \times N} - \frac{1}{n} - \frac{1}{N}}; 95\% \text{ CI} = e^{\ln(PR) \pm 1.96 \times SE} \right)$$

We extracted sex-specific and country-specific prevalence rates from the Global Burden of Diseases 2016 database for the year of data collection in the respective prison survey. The matching population size (N) was imputed from the 2017 Revision of World Population Prospects. Because a national reference for psychosis is not available, rates for schizophrenia were extracted and matched with prison study rates for schizophrenia, if available. If not, we used rates of non-affective psychotic illness. Prevalence ratios were pooled with random-effects meta-analysis. Sensitivity analyses were conducted for studies reporting 6 month rates of severe mental illness; and for schizophrenia, without imputed values of psychotic disorders.

For the Global Burden of Diseases database see http://ghdx.healthdata.org/ gbd-results-tool

For more on the **World Bank's** Atlas method see https://data. worldbank.org/

For the **2017 Revision of World Population Prospects** see https://esa.un.org/unpd/wpp/ DataQuery



Figure 1: Study identification, screening and eligibility test, following the Preferred Reporting Items of Systematic Reviews (PRISMA)

DSM=Diagnostic and Statistical Manual of Mental Disorders. ICD=International Classification of Diseases.

Biased prevalence estimates might arise not only from the inclusion of studies with lower methodological quality but also from publication or small study bias.²² To assess publication bias, we drew funnel plots presenting prevalence estimates against their SEs and tested the asymmetry of the funnel plots with Egger's test,²⁴ when ten or more samples were available. All analyses were done with STATA (version 13). This study is registered with PROSPERO, number CRD42015020905.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of

	Country	WHO region	Sex	Sampling	Sample size	Non-response rate (%)	Interviewer	Diagnostic instrument	Diagnostic criteria	Quality appraisal score
Adesanya et al³	Nigeria	Africa	Male	Population	395	4.8	Not stated	Not stated	DSM-III-R	6
Andreoli et al6*†	Brazil	Americas	Male	Stratified random	1192	26.8	Trained non-clinician	CIDI	ICD-10	8
Andreoli et al6*†	Brazil	Americas	Female	Stratified random	617	10.5	Trained non-clinician	CIDI	ICD-10	9
Assadi et al ³⁶ †	Iran	Eastern Mediterranean	Male	Stratified random	351	12.3	Psychiatrist	SCID-CV	DSM-IV	9
Ayirolimeethal et al ³¹ ‡	India	Southeast Asia	Male	Population	222	3.5	Psychiatrist	MINI-Plus	Not stated	8
Ayirolimeethal et al ³¹ ‡	India	Southeast Asia	Female	Population	33	0.0	Psychiatrist	MINI-Plus	Not stated	7
Boşgelmez et al ⁴⁴	Turkey	Europe	Male	Stratified random	30	6.3	Psychiatrist, clinical psychologist	SCID	DSM-IV	7
Boşgelmez et al ⁴⁴	Turkey	Europe	Female	Stratified random	30	11.8	Psychiatrist, clinical psychologist	SCID	DSM-IV	7
Canazaro and Argimon ²⁷	Brazil	Americas	Female	Population	287	22.0	Psychology student, psychologist	SCID-CV	DSM-IV	8
El-Gilany et al³⁰†	Egypt	Eastern Mediterranean	Mixed	Stratified random	1350	0.5	Psychiatrist	SCID	DSM-IV	8
Goyal et al ³²	India	Southeast Asia	Male	Random	500	Not stated	Consultant	PSE	ICD-10	7
Joshi et al³⁵	India	Southeast Asia	Female	Population	50	Not stated	Psychiatrist	Not stated	DSM-IV TR	6
Kaya et al45*‡	Turkey	Europe	Male	Random	305	14·3	Psychiatric assistant, trainee psychiatrist	CIDI	DSM-IV	6
Kumar and Daria ³³	India	Southeast Asia	Male	Random	118	9.2	Psychiatrist	IPIS	ICD-10	7
Majekodunmi et al ^{39*} ‡	Nigeria	Africa	Male	Random	196	1.5	Psychiatrist	SCID	DSM-IV	8
Math et al³4†	India	Southeast Asia	Male	Population	5024	Not stated	Research assistant	MINI-Plus	Not stated	4
Mundt et al ^{7*} ‡	Chile	Americas	Male	Random	855	1.0	Field worker	CIDI	DSM-IV	9
Mundt et al ^{7*} ‡	Chile	Americas	Female	Random	153	1.0	Field worker	CIDI	DSM-IV	8
Mundt et al ²⁹	Chile	Americas	Male	Consecutive systematic	229	7.0	Clinical psychologist	MINI	DSM-IV	10
Mundt et al ²⁹	Chile	Americas	Female	Consecutive	198	7.0	Clinical psychologist	MINI	DSM-IV	9
Naidoo and Mkize ⁴⁰	South Africa	Africa	Male	Stratified systematic random	193	22.8	Psychiatrist	MINI	Not stated	7
Nanéma et al²5‡	Burkina Faso	Africa	Male	Systematic random	419	2.8	Medical student	MINI	ICD-10	6
Ndetei et al41†‡	South Sudan	Africa	Mixed	Population	192	53·5	Clinical psychologist	MINI-Plus	ICD-10	5
Niriella et al42	Sri Lanka	Southeast Asia	Male	Random	325	0.8	Trained research assistant	Not stated	ICD-10	7
Niriella et al42	Sri Lanka	Southeast Asia	Female	Random	68	0.8	Trained research assistant	Not stated	ICD-10	6
Pondé et al² ⁶	Brazil	Americas	Male	Random; population	497	4.0	Medical student	MINI-Plus	DSM-IV	7
Salifou et al43‡	Тодо	Africa	Female	Population	61	9.0	Psychiatrist, psychologist	Clinical Interview	DSM-V	7
Silva et al²8‡	Brazil	Americas	Male	Consecutive	466	3.0	Not stated	MINI-Plus	DSM-IV	7
Silva et al²8‡	Brazil	Americas	Female	Consecutive	91	3.0	Not stated	MINI-Plus	DSM-IV	6
Zamzam and Hatta ³⁷ †	Malaysia	Western Pacific	Female	Population	80	3.6	Trainee psychiatrist	CIDI	Not stated	7

CIDI=Composite International Diagnostic Interview. DSM=Diagnostic and Statistical Manual of Mental Disorders. ICD=International Classification of Diseases. IPIS=Indian Psychiatric Interview Schedule. MINI=Mini-International Neuropsychiatric Interview. PSE=Present State Examination. SCID=Structured Clinical Interview for DSM Disorders. *Results are based on 1 year coverage. †Study reported separate rate for schizophrenia. ‡Authors provided additional data.

Table 1: Studies reporting prevalence estimates for severe mental disorders or substance use disorders in prison populations of low-income and middle-income countries

the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

We identified 23 publications with 30 samples published between 1997 and 2018 (figure 1). They provided data from 13 different LMICs: Burkina Faso,²⁵ Brazil,^{6,2e-28} Chile,^{7,29} Egypt,³⁰ India,³¹⁻³⁵ Iran,³⁶ Malaysia,³⁷ Nigeria,^{38,39} South Africa,⁴⁰ South Sudan,⁴¹ Sri Lanka,⁴² Togo,⁴³ and Turkey.^{44,45} Five studies were written in languages other than English: two in French,^{25,43} two in Portuguese,^{77,28} and one in Turkish.⁴⁵ Of 14527 imprisoned individuals, 85% were men and the weighted mean age was 31-8 years. Approximately 93% of the participants were prisoners in wards, while 7% at arrival to prison (table 1; appendix).

1 year prevalence rates of psychotic disorders were reported in 22 samples involving 13135 individuals.^{6,7,25,26,28–37,40,41,45} The random-effects pooled prevalence was 6.2% (95% CI 4.0-8.6) with very high betweensample heterogeneity ($I^2=96$; p<0.001; figure 2). We noted 15.8 times (95% CI 8.7-28.9) higher rates of non-affective psychosis than in the general population (table 2). Meta-regression indicated lower prevalence of psychosis in studies with smaller sample sizes $(\beta = -0.076; p = 0.004)$, decreasing rates with longer time spent in prison (β =-0.146; p<0.001), and higher estimates in samples recruited at prison intake (β =0.186; p<0.001). In the multivariate model, only the elevated prevalence of admission samples remained significant (β =0.138; p=0.026; appendix). The pooled prevalence of psychosis was 3.9% (95% CI 2.8-5.8) in non-admission samples. For this subgroup, prevalence rates ranged from 0.7% to 10.4% with substantial heterogeneity ($I^2=87$; p<0.001) and were slightly higher in male (4.3%; 95% CI 2.9-6.0) than in female populations (2.5%; 1.5-3.7; data not shown). In the four admission samples,28,29 the prevalence varied between 8.6% and 26.6%.

We identified 26 samples reporting 1 year prevalence of major depression (n=13452).^{6,7,25,26,28-37,39-41,43-45} The pooled 1 year prevalence was 16.0% (95% CI 11.7-20.8) with substantial heterogeneity (12-98%; p<0.001; figure 2), indicating 6.0 times (95% CI 4.4-8.0) higher rates than in the general population (table 2). Meta-regression found increased prevalence of major depression at admission $(\beta=0.199; p=0.005)$ and lower estimates in larger samples (β =-0.116; p=0.039), of which only higher prevalence at prison intake remain significant in the multivariate model (β =0.168; p=0.017; appendix). The pooled estimate of major depression in non-admission samples was 13.2% (95% CI 9.5-17.4). For these individuals, prevalence varied from 1.0% to 32.0%, with very high heterogeneity (I2=97%; p<0.001), and averaged 13.8% (95% CI 9.7-18.4) in men and 15.2% (9.2-22.4) in women. At prison intake,28,29 the estimates ranged between 13.7% and 54.1%.

A	WHO region	n/N		Prevalence rate (95% CI)	Weig (%)
Male samples					
Silva et al ^{28*}	Americas	124/466		26.6 (22.8-30.8	3) 4.8
Mundt et al ^{29°}	Americas	51/229	_	22.3 (17.4–28.1	
Nanéma et al ²⁵	Africa	21/419	-	5.0 (3.3-7.5)	4.82
Naidoo and Mkize ⁴⁰	Africa	12/193		6.2 (3.6–10.6)	
Andreoli et al ⁶	Americas	56/1192	1 -	4.7 (3.6–6.1)	4.99
Pondé et al ²⁶	Americas	39/497		7.8 (5.8–10.5)	
Mundt et al ⁷	Americas	6/855		0.7 (0.3-1.5)	4.95
Assadi et al ³⁶	Eastern Mediterra		Г. 	/	
Kaya et al ⁴⁵				4.3 (2.6-6.9)	4.77
	Europe	16/305		5.2 (3.3-8.4)	4.73
Math et al ³⁴	Southeast Asia	116/5024	•	2.3 (1.9–2.8)	5.00
Goyal et al ³²	Southeast Asia	13/500	-	2.6 (1.5-4.4)	4.8
Kumar and Daria ³³	Southeast Asia	8/118		6.8 (3.5–12.8)	
Ayirolimeethal et al ³¹ Subtotal (I²=97%, p<0·	Southeast Asia	16/222		7·2 (4·5–11·4) 6·6 (3·7–10·2)	
	,			(3,,	
Female samples					
Silva et al ^{28°}	Americas	23/91		→ 25·3 (17·5–35·1	
Mundt et al ^{29°}	Americas	17/198	· · · ·	8.6 (5.4–13.3)	4.5
Andreoli et al ⁶	Americas	21/617	*	3.4 (2.2–5.1)	4·9
Mundt et al ⁷	Americas	2/153	-	1.3 (0.4–4.6)	4.4
Joshi et al ³⁵	Southeast Asia	2/50	-	4.0 (1.1-13.5)	3.5
, Ayirolimeethal et al ³¹	Southeast Asia	2/33	-	6.1 (1.7–19.6)	
Zamzam and Hatta ³⁷	Western Pacific	1/80	•	1.3 (0.2-6.7)	3.9
Subtotal (<i>I</i> ² =88%, p<0-				5.7 (1.9-11.0)	
Mixed samples					
Ndetei et al ⁴¹	Africa	20/192		10.4 (6.8-15.5)	4.5
El-Gilany et al ³⁰	Eastern Mediterra		-	2.0 (1.4-2.9)	5.0
Overall (1 ² =96%, p<0.0		incuit 27/1550		6.2 (4.0-8.6)	
B Male samples					
Silva et al ^{28°}	Americas	64/466		13.7 (10.9–17.2)	4.0
Mundt et al ^{29*}	Americas	124/229	_	● 54.1 (47.7-60.5)	4.6
Nanéma et al ²⁵	Africa	118/419		28.2 (24.1-32.7)	4.0
Majekodunmi et al ³⁹	Africa	62/196	_	31.6 (25.5-38.4)	
Naidoo and Mkize40	Africa	20/193		10.4 (6.8–15.5)	3.9
Pondé et al ²⁶	Americas	30/497	-	6.0 (4.3-8.5)	4.0
Andreoli et al ⁶	Americas	82/1192		6.9 (5.6–8.5)	4.0
Mundt et al ⁷	Americas	52/855			4.1
Assadi et al ³⁶	Eastern Mediterra		_	6·1 (4·7–7·9) 27·9 (23·5–32·8)	4.0
Boşqelmez et al ⁴⁴					3.0
Kaya et al ⁴⁵	Europe Europe	4/30 67/305		13·3 (5·3–29·7) 22·0 (17·7–26·9)	
/			_	, ,	4.0
Ayirolimeethal et al ³¹	Southeast Asia	6/222	•	2.7 (1.2–5.8)	3.9
Math et al ³⁴	Southeast Asia	457/5024	•	9.1 (8.3–9.9)	4.1
Kumar and Daria ³³	Southeast Asia	19/118		16.1 (10.6–23.8)	3.8
Goyal et al ³² Subtotal (I ² =98%, p<0-	Southeast Asia	81/500	\diamond	16·2 (13·2–19·7) 15·9 (11·1–21·4)	4·0 59·3
Female samples				.,	
Silva et al ^{28°}	Americas	25/91	_	27.5 (19.4–37.4)	3.7
Mundt et al ^{29°}	Americas				
Salifou et al ⁴³	Africa	86/198		43.4 (36.7-50.4)	3.9
		19/61		31.1 (20.9-43.6)	3.5
Andreoli et al ⁶	Americas	116/617		18.8 (15.9-22.1)	4.0
Mundt et al ⁷	Americas	17/153		11.1 (7.1–17.1)	3.8
Boşgelmez et al ⁴⁴	Europe	3/30		10.0 (3.5–25.6)	3.0
Ayirolimeethal et al ³¹	Southeast Asia	1/33	*	3.0 (0.5–15.3)	3.1
Joshi et al ³⁵	Southeast Asia	16/50	· · · · · ·	32.0 (20.8–45.8)	3.4
Zamzam and Hatta ³⁷ Subtotal (I²=91%, p<0·	Western Pacific	6/80		7·5 (3·5–15·4) 19·4(11·7–28·5)	3.6 32.5
				13.4(11.)-50.2)	22.2
Mixed samples	A. É. i	27/402		141(00.40=)	~ ~
Ndetei et al ⁴¹	Africa	27/192		14.1 (9.8–19.7)	3.9
El-Gilany et al ³⁰	Eastern Mediterra	nean 13/1350		1.0 (0.6–1.6)	4.1
Overall (I²=98%, p<0∙0	01)		$ \diamond$	16·0 (11·7–20·8)	100.0
			0 10 20 30 40 50	60	
			Prevalence (%)		

Figure 2: Random-effects meta-analyses of 1-year prevalence studies reporting psychotic disorders (A) and major depression (B) in prison populations in low-income and middle-income countries *Samples were recruited at intake to prison.

Findings of our sensitivity analysis on non-admission samples showed no significant variation in prevalence rates or prevalence ratios for severe mental illness in samples reporting only 6 month estimates. The prevalence ratio for samples reporting solely schizophrenia was 7.9 (95% CI 4.9-12.7) compared with the general population (appendix).

former were likely to be higher and more comparable to the literature coming from HIC.⁸ At prison intake,^{28,29} the 1 year prevalence of alcohol use disorders ranged from 13.6% to 42.3%, and for drug use disorders estimates were between 27.3% and 68.1%.

For substance use disorders, we considered admission and non-admission samples separately because the We identified 12 non-admission samples reporting 1 year prevalence of alcohol use disorders (n=9491).^{6,7,2,5,2,6,34-37,41,43} The pooled prevalence was 3.8%

	Study	Sex	Psychotic d	isorders		Major depression		
			Population prevalence	Prevalence ratio		Population prevalence	Prevalence ratio	
				Estimate	95% CI	-	Estimate	95% CI
Africa								
Burkina Faso	Nanéma et al²5	Men	0.12	41.67*	27.48-63.28	1.48	19.05	16-35-22-20
Nigeria	Majekodunmi et al ³⁹	Men				1.74	18.16	14.78-22.32
South Africa	Naidoo and Mkize40	Men	0.19	24·74*	13.10-46.70	2.21	4.71	3.11-7.12
South Sudan	Ndetei et al41	Mixed	0.13	32.31	16.44-63.50	1.97	7.16	5.05-10.15
Тодо	Salifou et al43	Women				2.45	12.69	8.74-18.44
Americas								
Brazil	Andreoli et al6	Men	0.22	8.64	5.74-12.99	1.95	3.54	2.87-4.36
Brazil	Pondé et al ²⁶	Men	0.22	27.27*	19.26-38.63	2.02	2.97	2.10-4.21
Brazil	Silva et al²8†	Men	0.22	120.91*	103.98–140.60	1.95	7.03	5.59-8.82
Brazil	Andreoli et al6	Women	0.20	7.50	3.96-14.22	4.26	4·37	3.70-5.15
Brazil	Silva et al²8†	Women	0.20	126.50*	88.87-180.07	4.26	6.46	4.62-9.01
Chile	Mundt et al ⁷	Men	0.23	3.04*	1.37-6.76	2.13	2.86	2.20-3.73
Chile	Mundt et al²9†	Men	0.23	96.96*	76.10-123.52	2.16	25.05	22.23-28.22
Chile	Mundt et al ⁷	Women	0.21	6.19*	1.56-24.63	3.79	2.93	1.87-4.59
Chile	Mundt et al²9†	Women	0.22	39.09*	24.82-61.57	3.61	12.02	10.25-14.10
Eastern Mediterranean								
Iran	Assadi et al ³⁶	Men	0.18	11.11	5.34-23.11	3.15	8.86	7.49–10.48
Egypt	El–Gilany et al ³⁰	Mixed	0.18	4.44	2.45-8.05	2.28	0.42	0.25-0.72
Europe								
Turkey	Boşgelmez et al44	Men				2.05	6.49	2.60-16.18
Turkey	Kaya et al45	Men	0.19	5.26*	1.72-16.08	2.02	10.88	8.80-13.44
Turkey	Boşgelmez et al44	Women				3.66	2.73	0.93-7.99
Southeast Asia	,,,							
India	Ayirolimeethal et al ³¹	Men	0.24	28.33*	17.41-46.11	1.82	1.48	0.67-3.27
India	Goyal et al ³²	Men	0.23	1.74	0.44-6.94	1.91	8.48	6.95-10.35
India	Kumar and Daria ³³	Men	0.23	14.78	5.65-38.68	1.90	8.47	5.61-12.79
India	Math et al ³⁴	Men	0.24	4.58	3.53-5.96	1.82	5.00	4.58-5.46
India	Ayirolimeethal et al ³¹	Women	0.23	13.04*	1.87-90.78	2.64	1.14	0.16-7.91
India	Joshi et al ³⁵	Women	0.23	17.39*	4.47-67.62	2.62	12·21	8.15-18.30
Western Pacific	,			, 55				
Malaysia	Zamzam and Hatta ³⁷	Women	0.26	5.00	0.74-33.75	1.57	4.78	2.21-10.31
Pooled prevalence ratio I		Total	l ² =97%	15.83	8.68-28.87	l ² =98%	5.95	4.41-8.03
Pooled prevalence ratio II (non-admission samples)		Men	l ² =93%	11.10	6.05-20.37	l ² =97%	6.30	4.35-9.13
Pooled prevalence ratio II (non-admission samples)		Women	l ² =0%	8.26	5.03-13.58	l²=89%	5.26	3.10-8.93
Pooled prevalence ratio II (non-admission samples)		Total	l ² =90%	10.68	6.68–17.06	l²=97%	5.31	3.94-7.19

*Admission samples.†Sample reported non-affective psychotic disorders; otherwise, prevalence of schizophrenia was extracted. Population prevalence refers to the sex-specific, country-specific, and year-specific rates in the general population retrieved from the Global Burden of Disease database 2016.

Table 2: Prevalence ratios of severe mental illness in prison populations in low-income and middle-income countries

1 year prevence it that be prevent 423 (379-465) MA Mond t al ² Male America 7/723 Shot al al ² Female America 39(1) Mund t al ² Female America 20/7466 Type previous Male America 20/7466 Type previous Male America 20/7466 Type previous Male America 20/746 Type previous Male America 20/746 Type previous Male America 20/74 Type previous Male America 20/74 Andeo la ²¹ Male America 20/75 Andeo la ²¹ Male America 10/74 Andeo la ²¹ Female America 10/75 Solution all ²¹ Female America 10/75 Andeo la ²¹ Male America 10/75 Solutional (* 99%, poo 001) Male America 10/75 Solutional (* 99%, poo 001) Male America	Α	Sex	WHO region	n/N		Prevalence rate (95% CI)	Weight (%)
Silva di all' Mule America 197/466 Mundt et all' Fernale 300 (27-43) NA Silva di all' Mule America 300 (27-43) NA Silva di all' Mule America 300 (27-43) NA Silva di all' Mule America 300 (27-46) NA Adnobi et all' Mule America 300 (27-46) NA Mundt et all' Mule America 300 (27-46) NA Mundt et all' Mule America 300 (27-46) NA Silva di all' Mule America 100 (37-7) 38 (27-46) NA Silva di all' Mule Am	1 year prevalence at intake to	prison					
Munde et al ¹⁰ Munde et al ¹⁰ Firmale Americas 27(19) Jee provisione tal ¹⁰ Pres provisione tal ¹⁰ Mule Americas 27(19) Jee provisione tal ¹⁰ Mule Americas 27(19) Jee provisione tal ¹⁰ Mule Americas 27(19) Andreoli et al ¹⁰ Mule Americas 27(10) Andreoli et al			Americas	197/466	_	42.3 (37.9-46.8)	NA
Silve at a ¹⁰ Finale America. 30(9) 1 year providence in non-admission sample: 1 year providence in non-admission sample: 1 year providence in non-admission sample: 1 year providence in non-admission sample: Much et a ¹⁰ Mule America. 12(119) Much et a ¹⁰ Mule America. 32(119) Much et a ¹⁰ Mule America. 31(5) Much et a ¹⁰ Mule Southeat Asia 70(5) Subted II ⁰ Finale America. 31(5) Much et a ¹⁰ Finale America. 32(5) Subted II ⁰ Finale America. 31(5) Much et a ¹⁰ Finale America. 32(5) Subted II ⁰ Subted II ⁰ Finale America. 32(5) Subted II ⁰ Subted II ⁰ Finale America. 32(5) Subted II ⁰ Subted	Mundt et al ²⁹				_		
Mundret si [®] Fermale Americas 27/198 Image: state st	Silva et al ²⁸	Female	Americas				NA
Naméra et al ¹⁶ Male Americas 15/497 Andreol et al ¹⁶ Male Americas 21/192 Andreol et al ¹⁶ Male Americas 23/192 Andreol et al ¹⁶ Male Americas 23/192 Saffor et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Southeast Aia 950 Sobietal (I ⁶ -956, p-0-001) Lifetime provalence Americas 12/71504 Andreol et al ¹⁶ Male Americas 16/7497 Andreol et al ¹⁶ Male Americas 15/929 Americas 19/95 Sobretal (I ⁶ -999, p-0-001) 19 19 19 19 19 19 19 19	Mundt et al ²⁹	Female	Americas		_ -	• • •	NA
Naméra et al ¹⁶ Male Americas 15/497 Andreol et al ¹⁶ Male Americas 21/192 Andreol et al ¹⁶ Male Americas 23/192 Andreol et al ¹⁶ Male Americas 23/192 Saffor et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Americas 15/617 Andreol et al ¹⁶ Fernale Southeast Aia 950 Sobietal (I ⁶ -956, p-0-001) Lifetime provalence Americas 12/71504 Andreol et al ¹⁶ Male Americas 16/7497 Andreol et al ¹⁶ Male Americas 15/929 Americas 19/95 Sobretal (I ⁶ -999, p-0-001) 19 19 19 19 19 19 19 19	1 year prevalence in non-adm	ussion sam	nles				
Pende et al ^h Male Americas 12/1927 America et al ² Male Americas 23/1927 America et al ² Male Americas 23/1927 Mande et al ² Male Americas 23/1927 Mathe al ¹⁰ Male Southest Ais 20/1927 Mathe al ¹⁰ Female Americas 20/1927 America et al ² Female Americas 20/1927 Subtrat (l ¹⁰ Female Context Ais 20/2020 Lifetime prevalence Americas 20/1927 Copal et al ¹⁰ Male Americas 20/1928 1 1 1 1 1 1 1 1				19/419	+	4.5 (2.9-7.0)	8.66
Andredic all ^a Male Americas 23/1192 50 50 50 50 8-83 Assadi et all ^a Male Eastern Multierranen 0/15,11 50 10<	Pondé et al ²⁶	Male	Americas		•		8.70
Mundt et al ⁿ Male Americas 49855 Math et al ⁿ Male Southeast Aia 7095024 Andeoli et al ⁿ Female Americas 15617 Andeoli et al ⁿ Female Americas 15617 Subtrat (l ⁿ +98%, p-0-001) Lifeting prevalence Androi et al ⁿ Male Americas 122/1192 Toronde et al ⁿ Male Americas 122/1192 Toronde et al ⁿ Male Americas 120/1497 Subtrat (l ⁿ +98%, p-0-001) Lifeting prevalence Androi et al ⁿ Female Americas 120/1497 Subtrat (l ⁿ +98%, p-0-001) Lifeting prevalence Androi et al ⁿ Male Americas 120/1497 Subtrat (l ⁿ +99%, p-0-001) Lifeting prevalence Androi et al ⁿ Female Americas 120/1497 Kay et al ⁿ Male Americas 120/1497 Subtrat (l ⁿ +99%, p-0-001) Lifeting prevalence Americas 120/1497 Addes lifeting Prevalence Americas 120/1498 Lifeting Prevalenc	Andreoli et al ⁶	Male	Americas		•		8.83
Acadi et al ¹⁰ Male Extern Mediterranean 0/351 Safifocut al ¹⁰ Fernale Africa 3/061 Americas 1/561 Subtat al ¹⁰ Fernale Americas 1/553 Subbat at al ¹⁰ Fernale Americas 1/553 Subbat at al ¹⁰ Fernale Americas 2/20/20 Clifetime provalence Andreol et al ¹⁰ Male Americas 2/20/20 Subbat at al ¹⁰ Male Americas 3/6/5/7 Subbat at al ¹⁰ Male Americas 3/20/20/20 Subbat at al ¹⁰ Male Americas 3/20/20/20	Mundt et at ⁷	Male	Americas			/	
Math call Male Southeast Asia 703/5024 140 (131-150) 8-91 Saffuo et al Fernale America 15/617 24 (15-40) 8.7 Joshi et al Fernale America 15/617 24 (15-40) 8.7 Joshi et al Fernale America 15/617 24 (15-40) 8.7 Androli et al Mathe America 12/92 24 (15-40) 8.7 Androli et al Mathe America 20/92 20 26 (10-65) 8.3 Subtrati (* 99%, po-000) Watter Machine 27/92 36 (12-97.8) 100 (93.37) 12.6 Virtual Mahe America 22/91 20 3.8 12.707.0 100.00 Virtual Mahe Southeast Asia 27.750.4 11.700 38.6 (12-91.8) 12.8	Assadi et al ³⁶	Male	Eastern Mediterranean		•		8.61
Salifo et al ¹⁰ Female Africa 3/61 Andreoli et al ¹⁰ Female Americas 4/153 Sobte et al ¹⁰ Female Americas 4/153 Sobte at al ¹⁰ Africa 2/192 Valence Americas 1/192 Sobte at al ¹⁰ Male Americas 1/1920 Gogi et al ¹⁰ Male Entrom Mediterranean 7/1920 Coga et al ¹⁰ Male Southeast Asia 2/17/500 Americas 1/1920 Coga et al ¹⁰ Male Americas 2/11/192 Coga et al ¹⁰ Male Americas 2/11/	Math et al ³⁴				⊺		
Addeoli et al ¹⁶ Fenale Americas 15/617 Munde ti al ¹⁶ Fenale Americas 4/153 Joshi et al ¹⁶ Fenale Southeast Asia 9/50 Zinzam and Hatta ¹⁷ Fenale Southeast Asia 9/50 Zinzam and Hatta ¹⁷ Fenale Americas 2/2/192 Andreoli et al ¹⁶ Male Americas 15/192 Goal et al ¹⁶ Male Americas 15/192 Southeast Asia 2/17/500 Conde et al ¹⁶ Male Southeast Asia 2/17/500 Zinzam and Hatta ¹⁷ Fenale Americas 16/617 Fenale Americas 16/617 Fenale Americas 16/617 Fenale Americas 2/2/192 Andreoli et al ¹⁶ Male Americas 2/2/192 Andreoli et al ¹⁶ Male Americas 16/617 Fenale Americas 16/617 Fenale Americas 16/617 Fenale Americas 16/617 Fenale Americas 16/617 Fenale Americas 15/192 Munde et al ¹⁶ Male Americas 2/2/192 Andreoli et al ¹⁶ Male Americas 2/2/192 Americas 9/6/617 Fenale Americas 15/6127 Fenale Americas 15/6127 Fenale Americas 15/6129 Munde et al ¹⁶ Male Americas 2/2/466 Munde et al ¹⁶ Male Americas 15/6129 Munde et al ¹⁶ Male Americas 15/6129 Americas 15/6129 Fenale Americas 15/6129 Americas 15/6129 Fenale Americas 15/6129 Americas 15/6129 Fenale Americas 15/6129 Americas 15/6129 Fenale Americas 16/6149 Fenale Americas 1							
Mundt et al ^T Female Americas 4/153 26 (10 - 65) 8-23 Subteat al ^T Minde Subteat al ^T 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 38 (13 - 7.6) 100 - 9337 12 - 933 12 - 757 12 - 933 12 - 933 12 - 757 13 - 9338 12 - 757 13 - 9338 12 - 933 13 - 9338 13 - 9338 12 - 933 13 - 9338 <t< td=""><td></td><td></td><td></td><td></td><td>•</td><td></td><td></td></t<>					•		
johi ctal ¹⁰ Fernale Southeast Asia 9/50 Zumzan and Hatta ¹⁰ Fernale Western PAGINC 2/80 Niked et al ¹⁰ Miked Africa 2/192 Lifetime prevalence 10 (0.9-37) 38 (12-76) 100 0.90 Androlic tal ¹⁰ Male Americas 10/192 10 (0.9-37) 83 (12-76) 100 0.90 Lifetime prevalence Male Americas 10/192 10 (0.9-37) 18 (0.64-20.8) 11/79 Assidi tal ¹⁰ Male Europe 10/501 10 (0.9-37) 18 (0.64-20.8) 11/79 Goala tal ¹⁰ Male Southaat Akia 21/1902 10 (0.9-30) 18 (0.64-20.8) 11/79 Stap tal ¹⁰ Male Southaat Akia 21/1902 10 (0.9-20) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44) 13 (1.9-4.44)					-		
Zumam and Hatta ²⁷ Female Water Harm Pacific 2/80 2 2 2 2 0 3 6 3 8 10 0 3 5 3 8 10 0 3 5 3 8 10 0 3 6 10 0 3 6 10 0 3 6 10 0 3 6 10 0 3 6 10 0 3 6 10 0 3 6 10 0 <th0< th=""> 0 <th0< th=""></th0<></th0<>					· · · · · · · · · · · · · · · · · · ·		
Netesti et al ¹⁴ Mike Africa 2/192 Subto 1($f = 998, p-0.001$) If et min prevalence Andreolic ta al ¹⁶ Mike Americas 22/1/192 Fond et al ¹⁶ Mike Europe 105/351 Kay et al ¹⁶ Mike Europe 105/351 Kay et al ¹⁶ Mike Southeast Asia 227/5024 Andreolic ta al ¹⁶ Mike Southeast Asia 227/5024 Andreolic ta al ¹⁶ Mike Americas 96/617 Jazman and Hatta ²⁰ Female Americas 96/617 Jazman and Hatta ²⁰ Female Americas 156/229 Silva et al ¹⁶ Mike Americas 15/1192 Nandrea ta 1 ²⁷ Mike Americas 15/1192 Nandrea ta 1 ²⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Amdrea ta 1 ²⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Condit et al ¹⁸ Female Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Americas 110/53 Silva et al ¹⁸ Mike Southeast Asia 32/50 Condit et al ¹⁸ Female Americas 110/53 Sil	· ·				-		
Subtotal (F=98%, pc0-001) 38 (12-76) 100-00 Lifetime prevalence Andreoil et al ¹⁰ Kaya et al ¹⁰ Male Male Americas Americas 15/1497 Subtotal (F=98%, pc0-001) Male Europe Southeast Asia 217/1500 Kaya et al ¹⁰ Math et al ¹⁰ Andreoil et al ¹⁰ Andreoil et al ¹⁰ Female Male Americas Southeast Asia 217/1500 Subtotal (F=99%, p-0-001) Female Americas 15/275 36 (12-97.8) 12/29 B Subtotal (F=99%, p-0-001) Female Americas 22/04/66 10 20 30 40 50 B Issue tal ²⁰ Subtotal (F=99%, p-0-001) Male Americas Americas 22/04/66 472 (427-517) NA Silve tal ²⁰ Andreoil et al ²⁰ Mande et al ²⁰ Man							
Lifetime prevalence Andreolie tal ^{al} Male Male Americas Americas 122/1192 125/14/97 222 (18.2-509) 12.57 125 (12.5-79) 12.52 12.52 (18.2-509) 12.57 12.52 (18.2-509) 12.57 12.52 (18.2-509) 12.57 12.52 (18.2-509) 12.52 12.52 (18.2-509) 12.52 12.52 (18.2-509) 12.52 12.52 (18.2-329)		WIIXeu	Antea	2/192	\sim		
Andreolic all ^a Male Americas 12/11/12 Ansadi et all ^b Male Americas 16/14/97 Assadi et all ^b Male Estern Mediternaen 78/51 Kaya et all ^b Male Estern Mediternaen 78/51 Kaya et all ^b Male Southeast Asia 217/500 Andrecoli et all Male Southeast Asia 217/500 Andrecoli et all Male Southeast Asia 217/500 Subtotal (P=99%, p<0:001)					\sim	2 ())	
Ponde et al ¹⁶ Male Americas 15/1497 Kaya et al ¹⁶ Male Eastern Mediternaman 78/51 Kaya et al ¹⁶ Male Southeast Asia 217/500 Coylet al ¹⁰ Male Southeast Asia 217/3004 Math et al ¹⁶ Male Southeast Asia 217/3004 Andreoi et al ¹⁶ Female Americas 96/617 Zamzan and Hatta ¹⁷ Female Americas 15/6129 Subtoal (<i>P</i> =99%, pc0-001) B b b b b b c c c c c c c c		Mal-	Amoricas	221/1102		19 5 (16 4 20 9)	12 70
Assait al ¹⁶ Male Europe 105305 Goylet al ¹⁰ Male Southeast Asia 217/500 Andreal et al ¹⁰ Male Southeast Asia 217/500 Andreal et al ¹⁰ Female Americas 96/67 Subtrati (P=99%, p=0-001) B B B B B B B B B B B B B					-		
Kaya et al th Goyl et al th Math et al th Andreoil et al th Subtata (I ⁺ = 99x, pc-001) Male Southeast Asia 217/3504 Long 217/500 21/3504 Add (23) - 4/3 43 (43) - 4/4 b) 12.64 43 (43) - 4/4 b) B Female Subtata (I ⁺ = 99x, pc-001) Male Subtata (I ⁺ = 99x, pc-001) Male Subtata (I ⁺ = 99x, pc-001) Male Subtata (I ⁺ = 90x) Subtata (
Goyal et all? Male Southeast Asia 217/500 Andreol et all Female Americas 96/617 Subtotal (P =99%, p-0-001) Female Mericas 96/617 Subtotal (P =99%, p-0-001) Female Americas 96/617 Subtotal (P =99%, p-0-001) Female Americas 920/616 Sibotatal (P =99%, p-0-001) Female Americas 1/80 Subtotal (P =99%, p-0-001) Americas 1/56/229 30 40 50 B Subtotal (P =99%, p-0-001) Male Americas 1/56/239 NA 472 (427-517) NA Silva et all? Male Americas 1/56/239 Americas 5/519 43 (27-67) 933 Adesanyaet all? Male Africa 11/395 28 (16-4-9) 39 1/66 (18-77, 39) NA Adresanyaet all? Male Africa 11/395 24 (16-4-9) 39 36 (18-77, 7) 93 Andreol et all? Male Africa 11/395 30 43 (27-67) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>							
Math et all ^H Andreol et all ^H Andreol et all ^H Subtat (l ² = 99%, p-0 001) Male Female Western Pacific 2173/5024 96/617 11/80 Image: Female Pack of 12 > 48 Female P					_	, ,	
Andreoli et al ⁶ Subtatal (f ² = 99%, p-0 001) Female Female Americas Western Pacific 96/612 11/80 Image: 100 model Image: 11/80 Image: 11/80 Image: 100 model Image: 11/80 Image: 100 model Image: 11/80 Image:							
Zamzam and Hatta ²⁷ Subtatal (P =99%, p-0-001) Female Western Pacific 11/80 B I year prevalence at intake to prison Silva et al ¹⁸ Male Americas 156/229 Silva et al ¹⁸ Male Americas 156/229 Silva et al ¹⁹ Mundt et al ²⁹ Female Americas 156/29 Silva et al ¹⁹ Male Africa 11/395 Adesamp et al ¹⁹ Male Americas 156/198 I year prevalence in non-admission samples Nandreol et al ¹⁹ Male Americas 15/192 Adesamp et al ¹⁹ Male Americas 10/153 Silva et al ¹⁹ Male Americas 10/153 Silva et al ¹⁹ Male Americas 10/153 Silva et al ¹⁹ Male Americas 10/153 Added let al ¹⁰ Female Americas 10/153 Female Americas 10/153 Female Americas 11/192 Female Americas 11/192 Female Americas 11/192 Female Americas 11/192 Female Southest Asia 32/2/50 Female Americas 11/282 Female Americas 11/28 Female A					+		
Subtotal (ℓ = 99%, p=0-001) 27.6 (18.6-37.7) 100.00 B 1 20 30 40 50 1 year prevalence at intake to prison 50 47.2 (42.7-51.7) NA Silva et al ¹⁸ Male Americas 156/229 44.9 (57.23) NA 9 and real at al ¹⁸ Male Americas 156/229 43.2 (27-67) 9.93 Adsanya et al ¹⁸ Male Africa 18/419 43.2 (27-67) 9.93 Adsanya et al ¹⁸ Male Americas 15/1192 13.3 (0.8-2.1) 10.47 Pondé et al ¹⁸ Male Americas 15/1192 13.2 (0.8-2.3) 10.47 Pondé et al ¹⁸ Male Americas 15/1192 13.3 (0.8-2.1) 10.47 Pondé et al ¹⁸ Male Americas 10/153 33.2 (0.8-1.1) 10.6 Andreoli et al ¹⁶ Male Americas 10/157 16.0 (0.9-3.0) 10.97 Salifour et al ¹⁹ Female Americas 10/157 16.0 (0.2-1.0) 13.3 (0.8-2.1) 13.3 (0.8-2.3) 10.97 Salifour et al ¹⁹ Male Eastern							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Zamzam and Hatta ³⁷	Female	Western Pacific	11/80		13.8 (7.9–23.0)	
B Silva et al ¹² Male Americas 220/466 Silva et al ¹² Male Americas 156/229 Silva et al ¹² Male Americas 54/198 Aundt et al ¹⁹ Female Americas 54/198 Name al ¹⁵ Male Africa 18/19 Name al ¹⁵ Male Africa 18/19 Adesanya et al ¹⁵ Male Africa 18/19 Andreoli et al ¹⁶ Male Africa 18/19 Sadit et al ¹⁶ Male Americas 57/192 Pondé et al ¹⁶ Male Americas 57/192 Sadit et al ¹⁶ Male Americas 10/617 Mundt et al ¹⁶ Female Americas 10/617 Sadit et al ¹⁶ Female Americas 10/617 Mundt et al ¹⁶ Female Americas 10/617 Sadit et al ¹⁶ Female Americas 10/617 Mundt et al ¹⁶ Male Americas 10/617 Sa	Subtotal (l² =99%, p<0.001)					27.6 (18.6–37.7)	100.00
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1 year prevalence at intake to		Amoricas	220/466			
Silva et al ¹⁶ Female Americas 45/91 Mundt et al ¹⁹ Female Americas 54/198 1 year prevalence in non-admission samples Addeanya et al ¹⁶ Male Africa 11/395 Addeanya et al ¹⁶ Male Africa 15/1192 Pondé et al ¹⁶ 43 (2.7-6.7) 993 Addeanya et al ¹⁶ Male Americas 15/1192 13 (0.8-2.1) 10.47 Pondé et al ¹⁶ Male Americas 15/1192 13 (0.8-2.1) 10.47 Pondé et al ¹⁶ Male Americas 10/617 33 (0.9-11.2) 6.82 Salifou et al ¹⁶ Male Americas 10/617 11.1 (8.2-14.8) 9.78 Salifou et al ¹⁶ Female Americas 10/617 11.1 (8.2-16.8) 13 (0.9-11.2) 6.82 Vandt et al ¹⁷ Female Southeast Asia 3/50 13 (0.9-12.2) 6.82 13 (0.9-12.2) 6.82 Zamzam & Hatta ²⁷ Female Male Americas 148/497 40 (8.7-77) 9.91 Andreoli et al ¹⁶ Male Americas 12/5024 44 (8.27-77) 9.							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $							
1 year prevalence in non-admission samples Nanéma et al ²⁵ Male Africa 18/419 Adesanya et al ³⁸ Male Africa 11/395 Adesanya et al ³⁸ Male Americas 15/1192 Pondé et al ⁶⁵ Male Americas 15/1192 Pondé et al ⁶⁶ Male Americas 57/855 Assadi et al ⁶⁶ Male Americas 10/617 Sulfou et al ⁶⁷ Male Americas 10/617 Andreoli et al ⁶⁷ Female Americas 10/617 Mundt et al ⁷⁶ Female Americas 10/617 Mundt et al ⁷⁶ Female Americas 10/617 Mundt et al ⁷⁶ Female Americas 10/617 Subtotal (l ⁶ =92%, pc-0.001) Female Southeast Asia 3/50 Lifetime prevalence 113 (6.0-20.0) 7.46 Adreoli et al ⁶⁶ Male Southeast Asia 32/50 Gogal et al ¹⁶⁵ Male Southeast Asia 32/50 Gogal et al ¹⁶⁶ Male Southeast Asia 32/500 Cond et al ⁶⁶ Male<							
Nameria et al ²⁵ Male Africa 18/419 43 (27-67) 9 93 Adesanya et al ²⁶ Male Americas 15/192 28 (16-4.9) 9.89 Andreoli et al ⁶ Male Americas 5/192 30 (8-2.1) 10.47 Pondé et al ²⁶ Male Americas 5/7855 67 (52-85) 1035 Assadi et al ²⁶ Male Americas 10/153 30 (9-11.2) 6.82 Andreoli et al ⁶ Female Americas 10/153 60 (21-162) 6.31 Mundt et al ⁷ Female Americas 10/153 60 (21-162) 6.31 Joshi et al ²⁵ Female Southeast Asia 3/50 316 (19-20, 7.46 51 (2-9-7.8) 100.000 Zamzam & Hatta ²⁷ Female Male Eastern Mediterranean 265/351 51 (2-9-7.8) 104 (80-13.4) 9.17 Assad et al ⁶⁶ Male Americas 116/192 755 (70.77.97) 9.14 Pondé et al ⁶⁶ Male Southeast Asia 32/500 755 (70.77.97) 9.14 Caparate al ⁶⁶ Male Southeast Asia 32/502 </td <td>Monatera</td> <td>Ternale</td> <td>Americas</td> <td>54/190</td> <td>· ·</td> <td>21.2 (21.2-22.3)</td> <td>INA</td>	Monatera	Ternale	Americas	54/190	· ·	21.2 (21.2-22.3)	INA
Adesanya et al ³⁸ Male Africa 11/395 28 (16-4.9) 9.89 Andreoli et al ⁶ Male Americas 15/1192 13 (08-2:1) 10.47 Pondé et al ⁶⁵ Male Americas 57/855 67 67 (52-85) 10.35 Andreoli et al ⁶⁵ Male Americas 2/61 67 (52-85) 10.35 Salifou et al ⁶³ Female Americas 10/617 16 (09-3.0) 10.19 Mundt et al ⁷ Female Americas 10/617 16 (09-3.0) 10.31 Mundt et al ⁷ Female Americas 10/617 13 (08-2-10.0) 765 (36-11.6) 8.74 Joshi et al ⁵⁵ Female Americas 10/617 11 (18 (2-14.8) 9.78 Joshi et al ⁵⁵ Female Americas 10/617 11 (18 (2-14.8) 9.78 Zamzam & Hatta ²⁷ Female Male Americas 10/53 60 (21-162) 63.3 Zamzam & Hatta ²⁷ Female Male Americas 136/192 75 (70-77.7) 9.14 Kaya et al ¹⁶⁵ Male Eastern Mediterranean 26/5351 <t< td=""><td></td><td></td><td></td><td>18/410</td><td></td><td>4.3 (2.7-6.7)</td><td>0.03</td></t<>				18/410		4.3 (2.7-6.7)	0.03
Andreoli et al ⁶ Male Americas 15/1192 Pondé et al ⁶⁶ Male Americas 44/497 Mundt et al ⁷ Male Americas 57/855 Assadi et al ⁸⁶ Male Eastern Mediterranean 39/351 Salifou et al ⁶⁹ Female Americas 10/617 Mundt et al ⁷ Female Americas 10/617 Mundt et al ⁷ Female Americas 10/617 Mundt et al ⁷ Female Americas 10/617 Subtotal (l'=92%, p<0-001) Lifetime prevalence Andreoli et al ⁶⁶ Male Americas 116/1192 Pondé et al ⁸⁶ Male Eastern Mediterranean 265/351 Kaya et al ⁸⁶ Male Europe 39/305 Goyal et al ⁸⁶ Male Southeast Asia 322/500 Male Americas 113/287 Assadi et al ⁸⁶ Male Southeast Asia 322/5004 Male Americas 113/287 Andreoli et al ⁶⁶ Female Americas 113/287 Andreoli et al ⁶⁶ Female Americas 113/287 Andreoli et al ⁶⁶ Southeast Asia 325/5007 Subtotal (l'=99%, pc-0:001) Math et al ⁴¹ Male Southeast Asia 322/5004 Male Americas 113/287 Andreoli et al ⁶⁶ Female Americ					•	· · · · ·	
Pondé et al ²⁶ Male Americas 44/497 Mundt et al ⁷ Male Americas 57/855 Salifou et al ⁸⁶ Male Eastern Mediterranean 39/351 Salifou et al ⁸⁶ Female Americas 10/617 Mundt et al ⁷ Female Americas 10/153 Zanzam & Hatta ³⁷ Female Southeast Asia 3/50 Subtotal ($P=92\%$, p<0-001) Lifetime prevalence Andreoli et al ⁸⁶ Male Eastern Mediterranean 25/351 Assadi et al ²⁶ Male Americas 116/1192 Pondé et al ²⁶ Male Americas 148/497 Female Americas 148/497 Formale Southeast Asia 3/50 Lifetime prevalence Andreoli et al ⁸⁶ Male Eastern Mediterranean 25/351 Kaya et al ⁴⁶ Male Europe 39/305 Goyal et al ²⁶ Male Southeast Asia 52/5004 Math et al ¹⁶⁹ Male Southeast Asia 52/5004 Math et al ¹⁶⁹ Male Southeast Asia 52/5004 Math et al ¹⁶⁹ Female Americas 113/287 Andreoli et al ⁴⁶ Female Americas 126/517 Andreoli et al ⁴⁶ Female Americas 113/287 Andreoli et al ⁴⁷ Female Mericas 113/287 Andreoli et al ⁴⁶ Female Americas 113/287 Andreoli et al ⁴⁷ Female Mericas 113/287 Andreol	· ·						
$\begin{array}{cccccccccccccccccccccccccccccccccccc$							
Assadi et al ³⁶ Male Eastern Mediterranean $39/351$ III (82-14.8) 978 Salifou et al ⁴³ Female Africa $2/61$ III (82-14.8) 978 Andreoli et al ⁶ Female Americas $10/617$ IEG (0.9-30) 10.9 Mundt et al ⁷ Female Americas $10/153$ IEG (0.9-30) 10.9 Joshi et al ⁷⁵ Female Southeast Asia $3/50$ IEG (0.2-0.0) 7.46 Subtotal (l ² =92%, p-0-001) Female Americas $116/192$ III (8.2-14.8) 9.978 Lifetime prevalence III (8.2-14.8) 9.80 III (8.2-14.8) 9.978 $60.(2.1-16.2)$ 6.31 Assadi et al ²⁶ Male Americas $116/192$ 20.978 20.978 9.917 Assadi et al ²⁶ Male Eastern Mediterranean $265/351$ $48/497$ $28.(259-33.9)$ 9.17 Assadi et al ²⁶ Male Southeast Asia $322/502$ $44.(8.0-13.4)$ 9.17 Math et al ²⁴ Male Southeast Asia $322/502$ $44.0(38.7-49.4)$ 9.13							
Salifou et al ⁴³ Female Africa $2/61$ $3/3 (0.9-11.2)$ 6.82 Andreoli et al ⁶ Female Americas $10/153$ $16 (0.9-3.0)$ 10.19 Joshi et al ¹⁵ Female Subtest Asia $3/50.9-11.2$ 6.82 Zamzam & Hatta ³⁷ Female Americas $10/153$ $6.5 (3.6-11.6)$ 6.74 Joshi et al ¹⁵ Female Western Pacific $9/80$ $5.1 (2.9-7.8)$ 100.000 Lifetime prevalence Ital ⁶ Male Americas $148/497$ $5.1 (2.9-7.8)$ 100.000 Lifetime prevalence Ital ⁶ Male Americas $148/497$ $5.2 (5.02-77.9)^2$ 9.21 Axy at al ¹⁵⁵ Male Eastern Mediterranean $265/351$ $48/497$ $7.5 (70.7-79.7)$ 9.14 Kaya et al ¹⁵⁵ Male Southeast Asia $32/2/500$ $4.48/497$ $4.48/497$ $4.48/497$ $4.49/68/68-7.1)$ 9.24 Andreoli et al ⁶⁶ Male Southeast Asia $32/2/5024$ $4.40/(38.7-49.4)$ 9.13 Canazaro & Argimon ⁷⁷ Female Americas $13/287$							
Andreoli et al ⁶ Female Americas 10/617 Mundt et al ⁷ Female Americas 10/153 Joshi et al ⁵⁵ Female Southeast Asia 3/50 Subtotal (l²=92%, p<0-001)						· ,	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							
Zamzam & Hatta ³⁷ Female Western Pacific 9/80 11.3 (6.0-20.0) 7.46 Subtotal (l ² =92%, p<0-001)							
Subtotal (l²=92%, p<0-001)	· ·						
Andreoli et al ⁶ Male Americas 316/1192 Pondé et al ⁶ Male Americas 148/497 Assadi et al ³⁶ Male Eastern Mediterranean 265/351 Kaya et al ³⁵ Male Europe 39/305 Goyal et al ³² Male Southeast Asia 52/500 Math et al ³⁴ Male Southeast Asia 322/5024 Niriella et al ⁴² Male Southeast Asia 13/325 Canazaro & Argimon ²⁷ Female Americas 113/287 Andreoli et al ⁶ Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Quot du (P=99%, p<0-001)		i cindic	Western dene	5,00	\diamond		
Andreoli et al ⁶ Male Americas 316/1192 Pondé et al ⁶ Male Americas 148/497 Assadi et al ³⁶ Male Eastern Mediterranean 265/351 Kaya et al ³⁵ Male Europe 39/305 Goyal et al ³² Male Southeast Asia 52/500 Math et al ³⁴ Male Southeast Asia 322/5024 Niriella et al ⁴² Male Southeast Asia 13/325 Canazaro & Argimon ²⁷ Female Americas 113/287 Andreoli et al ⁶ Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Quot du (P=99%, p<0-001)	Lifetime prevalence						
Pondé et al ²⁶ Male Americas 148/497 Assadi et al ⁵⁶ Male Eastern Mediterranean 265/351 Kaya et al ⁴⁵ Male Europe 39/305 Goyal et al ⁵² Male Southeast Asia 52/500 Math et al ³⁴ Male Southeast Asia 322/5024 Niriella et al ⁴² Male Southeast Asia 143/325 Canazaro & Argimon ²⁷⁷ Female Americas 113/287 Andreoli et al ⁶ Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Southeast Asia 24/68 Subtotal (l²=99%, p<0-001)		Male	Americas	316/1192	•	26.5 (24.1-29.1)	Q.71
Assadi et al ³⁶ Male Eastern Mediterranean 265/351 Kaya et al ⁴⁵ Male Europe 39/305 Goyal et al ³² Male Southeast Asia 52/500 Math et al ³⁴ Male Southeast Asia 322/5024 Niriella et al ⁴² Male Southeast Asia 322/5024 Canazaro & Argimon ²⁷ Female Americas 113/287 Andreoli et al ⁶ Female Americas 155/617 Niriella et al ⁴² Female Southeast Asia 24/68 Zamzarn and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (l ² =99%, p<0-001)					-		
Kaya et al ⁴⁵ Male Europe 39/305 12.8 (9.5-17.0) 9.12 Goyal et al ⁵² Male Southeast Asia 52/500 10.4 (8.0-13.4) 9.17 Math et al ³⁴ Male Southeast Asia 322/5024 64 (5.8-7.1) 9.24 Niriella et al ⁴² Male Southeast Asia 143/325 -4- 44.0 (38.7-49.4) 9.13 Canazaro & Argimon ²⁷ Female Americas 113/287 -4- 39.4 (33.9-45.1) 9.12 Andreoli et al ⁶ Female Americas 155/617 -4- 25.1 (21.9-28.7) 9.19 Niriella et al ⁴² Female Southeast Asia 24/68 35.3 (25.0-47.2) 8.72 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 -40 50.0 (39.3-60.7) 8.79 Subtotal (l ² =99%, p<0-001)							
Goyal et al ³² Male Southeast Asia 52/500 • 10.4 (8.0-13.4) 9.17 Math et al ³⁴ Male Southeast Asia 322/5024 • 64 (5.8-7.1) 9.24 Niriella et al ⁴² Male Southeast Asia 13/287 44.0 (38.7-49.4) 9.12 Andreoli et al ⁶⁶ Female Americas 113/287 - 25.1 (21.9-28.7) 9.19 Niriella et al ⁴² Female Southeast Asia 24/68 35.3 (25.0-47.2) 8.72 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 - - 30.6 (18.1-44.8) 100.00 Subtotal (l²=99%, p<0-001)					+		
Math et al ³⁴ Male Southeast Asia 322/5024 6-4 (5-8-7.1) 9-24 Niriella et al ⁴² Male Southeast Asia 143/325 44-0 (38.7-49-4) 9-13 Canazaro & Argimon ²⁷ Female Americas 113/287 39-4 (33-9-45-1) 9-12 Andreoli et al ⁶ Female Southeast Asia 24/68 35-3 (25-0-47-2) 8-72 Zamzam and Hatta ²⁷ Female Western Pacific 40/80 50-0 (39.3-60.7) 8-79 Subtotal (P=99%, p<0-001)							
Niriella et al ⁴² Male Southeast Asia 143/325 Canazaro & Argimon ²⁷ Female Americas 113/287 Andreoli et al ⁶ Female Americas 155/617 Niriella et al ⁴² Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (l ² =99%, p<0-001)	/						
Canazaro & Argimon ²⁷ Female Americas 113/287 Andreoli et al ⁶ Female Americas 155/617 Niriella et al ⁴² Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (P=99%, p<0-001)							
Andreoli et al ⁶ Female Americas 155/617 Niriella et al ⁴² Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (P=99%, p<0-001)							
Niriella et al ⁴² Female Southeast Asia 24/68 Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (l ² =99%, p<0-001)							
Zamzam and Hatta ³⁷ Female Western Pacific 40/80 Subtotal (l ² =99%, p<0.001) Female Western Pacific 40/80 0 20 40 60 80					-		
Subtotal (<i>P</i> =99%, p<0.001) 30.6 (18.1-44.8) 100.00 0 20 40 60 80							
0 20 40 60 80		⊦emale	western Pacific	40/80			
	500totai (1=99%, p<0∙001)					(10-1-44-8) م.م.	100.00
Prevalence (%)					6 20 40 60 80		
					Prevalence (%)		

Figure 3: Random-effects meta-analysis of prevalence studies reporting alcohol use disorders (A) and drug use disorders (B) in prison populations in **low-income and middle-income countries** NA=not applicable.

	Study	Sex	Alcohol use	disorders		Drug use disorders		
			Population prevalence	Prevalence ratio		Population prevalence	Prevalence ratio	
				Estimate	95% CI	-	Estimate	95% Cl
Africa								
Burkina Faso	Nanéma et al²5	Men	1.00	4.50	2.90-7.00	0.39	11.03	7.02–17.32
Nigeria	Adesanya et al ³⁸	Men				0.37	7.57	4.23-13.53
South Sudan	Ndetei et al40	Mixed	1.11	0.90	0.22-3.68			
Тодо	Salifou et al43	Women	0.96	5.10	1.69–15.42	0.30	11.00	2.83-42.80
Americas								
Brazil	Andreoli et al ⁶	Men	4·28	0.44	0.30-0.67	1.30	1.00	0.61-1.64
Brazil	Pondé et al²6	Men	4.29	0.70	0.42-1.15	1.27	7.01	5.29-9.28
Brazil	Silva et al²8*	Men	4.28	9.88	8.89-10.99	1.30	36.31	32.98-39.97
Brazil	Andreoli et al6	Women	1.38	1.74	1.05-2.88	0.72	2.22	1.20-4.13
Brazil	Silva et al²8*	Women	1.38	23.91	17.84-32.05	0.72	68.75	55.87-84.61
Chile	Mundt et al ⁷	Men	3.78	1.32	0.99-1.77	1.38	4.86	3.78-6.24
Chile	Mundt et al ^{29*}	Men	3.60	9.33	7.78–11.20	1.44	47·29	43.27-51.68
Chile	Mundt et al ⁷	Women	1.46	1.78	0.68-4.70	0.78	8.33	4·57–15·20
Chile	Mundt et al ^{29*}	Women	1.40	9.71	6.84-13.80	0.80	34·13	27.18-42.84
Eastern Mediterranean								
Iran	Assadi et al ³⁶	Men	0.64	0.22	0.01-3.58	2.50	4.44	3.30-5.97
Southeast Asia								
India	Math et al ³⁴	Men	2.03	6.90	6.44-7.39			
India	Joshi et al³⁵	Women	0.43	41.86	23.17-75.64	0.37	16.22	5.41-48.58
Western Pacific								
Malaysia	Zamzam and Hatta ³⁷	Women	0.32	7.81	1.99-30.70	0.54	20.83	11.26-38.56
Pooled prevalence ratio (non-admission samples)		Men	l²=99%	1.40	0.45-4.36	l²=92%	4.85	2.93-8.04
Pooled prevalence ratio (non-admission samples)		Women	l²=94%	5.54	1.23-24.92	l ² =86%	8.98	3.62-22.27
Pooled prevalence ratio (non-admission samples)		Total	l²=97%	2.43	1.12-5.24	I²=89%	6.11	3.98-9.39

Table 3: Prevalence ratios of substance use disorders in prison populations in low-income and middle-income countries

(95% CI 1.2-7.6; figure 3), 2.4 times higher than $(1 \cdot 1 - 5 \cdot 2)$ in the general population (table 3). The estimates ranged from 0.0% to 18.0% (I2=98%, p<0.001), and were similar for men (3.7%, 95% CI 0.5-9.4) and women (4.4%, 1.5-8.4; figure 3). Metaregression indicated geographical variation, with elevated prevalence in the southeast Asian region in comparison to the eastern Mediterranean region $(\beta=0.140; p=0.038; appendix)$. We recorded higher estimates in lower quality studies ($\beta = -0.024$; p=0.001), which could be attributed to two lower quality studies with high prevalence estimates from the southeast Asian region.^{34,35} The lifetime prevalence rate of alcohol use disorders (eight samples; n=8566)6,26,32,34,36,37 was 27.6% (95% CI 18.6-37.7; men: 32.2%, 22.3-43.0, and women: 15.2%, 12.6-18.0) and varied between 13.8% and 43.4% (I²=99%, p<0.001; figure 3). The small number of samples precluded further analyses.

For the 11 samples reporting 1 year prevalence rates of drug use disorders (n=4670), $^{67,25,26,35-38,43}$ the pooled estimate was 5 · 1% (95% CI 2 · 9-7 · 8), 5 · 3% (2 · 5-9 · 0) in male and 5.0% (1.6-9.8) in female samples ie, $6 \cdot 1$ times (95% CI $4 \cdot 0 - 9 \cdot 4$) higher than in the general population (table 3). The 1 year prevalence of drug use disorders ranged from $1 \cdot 3\%$ to $11 \cdot 3\%$ (*I*²=92%; p<0.001; figure 3). Findings of meta-regression did not show any significant explanation for heterogeneity (appendix). Studies on lifetime prevalence of drug use disorders (11 samples; n=9246)^{6,26,27,32,34,36,37,42} indicated a pooled estimate of 30.6% (95% CI 18.1-44.8; men: 27.2%, 95% CI 12·1-45·7, and women: 36·7%, 95% CI 25.9–48.2), ranging between 6.4% and 75.5% (*I*²=99%; p<0.001; figure 3). Meta-regression results showed geographical variation between samples with elevated prevalence in the eastern Mediterranean in comparison to the European region (β =0.627; p=0.019; appendix).

Egger's test of asymmetric funnel plot indicated small sample bias for psychotic illnesses (p=0.027), current alcohol use disorders (p=0.025) and for lifetime drug use disorders (p=0.013) in non-admission studies. After excluding the study with the lowest quality score, which also had the largest sample size,³⁴ evidence for publication bias did not remain significant (appendix).

Discussion

Our findings suggest that incarcerated individuals in LMICs have a higher prevalence of psychiatric disorders than the general population and that rates at arrival to prison are elevated. Furthermore, our results show that there is geographical variation in the prevalence of substance use disorders.

The study had several limitations. Our findings are based on only 13 of more than 100 LMICs, and we could not identify any studies meeting our criteria from China, which has the largest prison population among LMICs. Additionally, there was high heterogeneity between studies. This was not unexpected as the included countries are substantially different in terms of their criminal and health-care systems.

Consistent with systematic reviews from prisoners in HICs,⁴⁸ our findings provide evidence for higher prevalence of psychiatric disorders in incarcerated people than in the general population.^{46,47} Imprisoned individuals often have a low socioeconomic background, belong to minority groups, and have histories of childhood victimisation and substance abuse, which make them vulnerable to psychiatric disorders.^{9,48} While in prison, poor living conditions,³ physical assault²⁰ and psychological abuse⁵ can further contribute to mental health disorders.

Although general population reviews indicate a lower prevalence of schizophrenia⁴⁷ and major depression⁴⁶ in LMICs than in HICs, we did not find this among prisoners.⁴ A high prevalence of severe mental illness in prisoners in LMICs could relate to poorly developed community mental health-care systems that do not yet reach socially deprived and marginalised populations in these countries. Human rights violations among individuals with mental health problems during imprisonment, especially for those with psychotic conditions, have been reported to be more common in poorly resourced settings.⁵

Upon arrival to prison, we found similar 1 year prevalence estimates of alcohol and drug use disorders as those reported for individuals in HICs.⁸ These are comparable to lifetime rates and provide information about the substance use problems before imprisonment. However, the estimates on current prevalence among non-intake samples represent the average disease burden during imprisonment, which might be relevant for service planning. Even though addictive substances are available in most prisons in LMICs,⁴⁸ the prevalence of substance use disorders for this population is substantially lower during imprisonment than for the same population while outside of prison. We found regional variation in the prevalence of substance use disorders, possibly linked to regional differences of the substances used.48 The highest rates of alcohol use disorders were found in studies from India,^{34,35} while the highest rate for drug use disorders was reported in a study from Iran.36 While lower rates of substance use disorders in women are found in the general population,46 this is typically not the case for prison populations. The rates of substance use disorders among prisoners start considerably higher than population comparisons independent of sex, likely due to substance use being a major driver of criminality.49 In HICs. incarcerated women have similar rates of alcohol use disorders as incarcerated men and a higher prevalence of illicit drug use disorders than men.8 This difference can be explained by lower rates of female incarceration and hence women in prison being a more selected group of high-risk individuals with elevated rates of substance use problems.

Admission studies indicated higher rates of psychosis and major depression at arrival to prison compared with investigations that included prisoners at later stages of imprisonment, which is consistent with longitudinal studies from HICs reporting high rates of psychiatric disorders at intake to prison.^{50,51} However, this finding was based on only two intake studies conducted in Latin American countries. The very high prevalence of severe mental illness at intake to prison in those countries could be linked to the use of cocaine products before imprisonment.^{29,48,51} There are several possible explanations for lower rates of mental health symptoms at later stages of imprisonment in spite of the harsh conditions of LMICs prisons including: reduced access to substances during imprisonment, protection or removal from adverse social environments outside of prisons, development of coping mechanisms,50 some availability of treatment services, and diversion of mentally ill prisoners.3 However, the literature points to substantial unmet health-care needs.³

Our findings have several implications. First, the low number of included samples emphasises the paucity of epidemiological investigations in LMICs. Although more than 100 high quality samples provide reliable evidence of psychiatric disorders in prisons in HICs,²⁰ we found only 30 samples from a much more diverse group of countries. Further evidence is needed to adequately plan interventions for prisoners with mental disorders in LMICs, especially from regions underrepresented in research such as central and east Asia, and Central America. Second, cost-effective interventions and scalable treatments should be prioritised, either by adapting existing programmes from HICs to local conditions or by developing new programmes on a large scale (eg, interventions at the transition from prison to the community for individuals with mental illness).52,53 Effective psychological treatments in prison settings have been reported for HICs⁵² and some might be transferable to resource-poor settings. Furthermore, community interventions in LMICs, such as enhancing health literacy,54 using digital technologies in prevention,55 as well as treatments of severe mental disorders,⁵⁶ have shown promising ways of addressing the mental health treatment gap. Some of these interventions could also be used to prevent and treat psychiatric disorders in prison populations.

Finally, imprisonment could present an opportunity to treat people with mental health and substance use problems who otherwise would be difficult to reach for health services;⁴ however, neither the funding nor qualified staff for such treatments are usually available in prisons. National governments in LMICs should move the responsibility for prison health care from prison administrations to the national health services.⁵ In conclusion, our findings of high prevalence estimates for major mental health and substance use disorders among prisoners in LMICs present an important global mental health challenge, indicate a treatment gap, and might raise concerns about human rights violations.

Contributors

GB, APM, SF, VP, and SP conceived, planned, and oversaw the study. GB and CS searched the literature, applied inclusion and exclusion criteria, extracted data, and conducted quality assessment. Disagreements between reviewers were resolved by consensus with APM. GB, SF, and APM developed the methodology and conducted the statistical analyses. GB and APM drafted the manuscript; all authors reviewed, commented on, and approved it.

Declaration of interests

We declare no competing interests.

Acknowledgments

This work was funded by CONICYT of the Chilean government (FONDECYT Regular grant number 1160260 to APM) and the Wellcome Trust (grant number 202836/Z/16/Z to SF). We thank A Ayirolimeethal, A S Çilli, D Nanéma, D Ndetei, A Obadeji, M P Pondé, M I Rosa, and S Salifou for kindly providing additional information on their studies. We are grateful for C Gabrysch for participation in the screening of the studies.

References

1 Walmsley R. World Prison Population List (eleventh edition). London, UK: Institute for Criminal Policy Research, 2016.

- Cohen JE, Amon JJ. Health and human rights concerns of drug users in detention in Guangxi Province, China. *PLoS Med* 2008; 5: e234.
- 3 Almanzar S, Katz CL, Harry B. Treatment of mentally ill offenders in nine developing Latin American countries. J Am Acad Psychiatry Law 2015; 43: 340–49.
- 4 Fazel S, Seewald K. Severe mental illness in 33588 prisoners worldwide: systematic review and meta-regression analysis. *Br J Psychiatry* 2012; 200: 364–73.
- 5 Jack HE, Fricchione G, Chibanda D, Thornicroft G, Machando D, Kidia K. Mental health of incarcerated people: a global call to action. *Lancet Psychiatry* 2018; 5: 391–92.
- 6 Andreoli SB, Dos Santos MM, Quintana MI, et al. Prevalence of mental disorders among prisoners in the state of Sao Paulo, Brazil. *PLoS One* 2014; 9: e88836.
- 7 Mundt AP, Alvarado R, Fritsch R, et al. Prevalence Rates of Mental Disorders in Chilean Prisons. *PLoS One* 2013; **8**: e69109.
- 8 Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an updated systematic review and meta-regression analysis in recently incarcerated men and women. *Addiction* 2017; **112**: 1725–39.
- 9 Baranyi G, Cassidy M, Fazel S, Priebe S, Mundt AP. Prevalence of posttraumatic stress disorder in prisoners. *Epidemiol Rev* 2018; 40: 134–45.
- 10 Gates ML, Turney A, Ferguson E, Walker V, Staples-Horne M. Associations among substance use, mental health disorders, and self-harm in a prison population: examining group risk for suicide attempt. *Int J Environ Res Public Health* 2017; 14: 317.

- 11 Spittal MJ, Forsyth S, Borschmann R, Young JT, Kinner SA. Modifiable risk factors for external cause mortality after release from prison: a nested case-control study. *Epidemiol Psychiatr Sci* 2017; 28: 1–10.
- 12 Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009; 166: 103–09.
- 13 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
- 14 Tavares GP, Scheffer M, Martins de Almeida RM. Drugs, violence and emotional aspects in prisoners. *Psicol Reflex Crit* 2012; **25**: 89–95.
- 15 Fido AA, al-Jabally M. Presence of psychiatric morbidity in prison population in Kuwait. Ann Clin Psychiatry 1993; 5: 107–10.
- 16 Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 2014; 3: 123–28.
- 17 Kelley GA, Kelley KS. Statistical models for meta-analysis: a brief tutorial. World J Methodol 2012; 2: 27–32.
- Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014; 72: 39.
- 19 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
- 20 Fazel S, Hayes AJ, Bartellas K, Clerici M, Trestman R. Mental health of prisoners: prevalence, adverse outcomes, and interventions. *Lancet Psychiatry* 2016; 3: 871–81.
- 21 Jackson D, Law M, Rucker G, Schwarzer G. The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns? *Stat Med* 2017; 36: 3923–34.
- 22 Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March 2011. The Cochrane Collaboration, 2011. http://handbook.cochrane.org (accessed July 20, 2018).
- 23 Beijer U, Wolf A, Fazel S. Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. *Lancet Infect Dis* 2012; 12: 859–70.
- 24 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997; 315: 629–34.
- 25 Nanéma D, Goumbri P, Karfo K, Ouango JG, Ouédraogo A. Epidemiological and clinical aspects of mental disorders in prisons in Ouagadougou, Burkina Faso. Annales Africaines de Psychiatrie 2014; 3: 59–75 (in French).
- 26 Pondé MP, Freire AC, Mendonca MS. The prevalence of mental disorders in prisoners in the city of Salvador, Bahia, Brazil. *J Forensic Sci* 2011; 56: 679–82.
- 27 Canazaro D, de Lima Argimon II. Characteristics, depressive symptoms, and associated factors in incarcerated women in the State of Rio Grande do Sul, Brazil. *Cad Saude Publica* 2010; 26: 1323–33 (in Portuguese).
- 28 Silva NC, Rosa MI, Amboni G, Mina F, Comim CM, Quevedo J. Psychiatric disorders and risk factors in a prison population. ACM arq catarin med 2011; 40: 72–76 (in Portuguese).
- 29 Mundt AP, Kastner S, Larraín S, Fritsch R, Priebe S. Prevalence of mental disorders at admission to the penal justice system in emerging countries: a study from Chile. *Epidemiol Psychiatr Sci* 2016; 25: 441–49.
- 30 El-Gilany A, Khater M, Gomaa Z, Hussein E, Hamdy I. Psychiatric disorders among prisoners: a national study in Egypt. *East Asian Arch Psychiatry* 2016; 26: 30–38.
- 31 Ayirolimeethal A, Ragesh G, Ramanujam JM, George B. Psychiatric morbidity among prisoners. *Indian J Psychiatry* 2014; 56: 150–53.
- 32 Goyal SK, Singh P, Gargi PD, Goyal S, Garg A. Psychiatric morbidity in prisoners. Indian J Psychiatry 2011; 53: 253–57.
- 33 Kumar V, Daria U. Psychiatric morbidity in prisoners. Indian J Psychiatry 2013; 55: 366–70.
- 34 Math SB, Murthy P, Parthasarathy R, Kumar CD, Madhusudhan S. Mental health and substance use problems in prisons. The Bangalore prison mental health study: local lessons for national action. Bangalore, India: National Institute of Mental Health and Neuro Sciences; 2011.

- 35 Joshi P, Kukreja S, Desousa A, Shah N, Shrivastava A. Psychopathology and other contributing stressful factors in female offenders: an exploratory study. *Indian J Forensic Med Toxicol* 2014; 8: 149–55.
- 36 Assadi SM, Noroozian M, Pakravannejad M, et al. Psychiatric morbidity among sentenced prisoners: prevalence study in Iran. Br J Psychiatry 2006; 188: 159–64.
- 37 Zamzam R, Hatta SM. Specific psychiatric disorders among convicted female offenders in a Malaysian prison. *Malaysian J Psychiatry* 2000; 8: 34–42.
- 38 Adesanya A, Ohaeri JU, Ogunlesi AO, Adamson TA, Odejide OA. Psychoactive substance abuse among inmates of a Nigerian prison population. *Drug Alcohol Depend* 1997; 47: 39–44.
- 39 Majekodunmi O, Obadeji A, Oluwole L, Oyelami R. Depression in prison population: Demographic and clinical predictors. *J Forensic Sci Med* 2017; 3: 122–27.
- 40 Naidoo S, Mkize DL. Prevalence of mental disorders in a prison population in Durban, South Africa. Afr J Psychiatry 2012; 15: 30–35.
- 41 Ndetei D, Khasakhala L, Mutiso V, Harder V. Mental disorders and HIV risk behaviors among prisoners in South Sudan. Nairobi, Kenya: United Nations Office On Drugs And Crime (UNODC), 2008.
- 42 Niriella MA, Hapangama A, Luke HP, Pathmeswaran A, Kuruppuarachchi KA, de Silva HJ. Prevalence of hepatitis B and hepatitis C infections and their relationship to injectable drug use in a cohort of Sri Lankan prison inmates. *Ceylon Med J* 2015; 60: 18–20.
- 43 Salifou S, Wenkourama D, Soedje KMA, Anagonou L, Agouda B, Dassa KS. Mental health of women detained in the civil prison of Lome. *Health Sci Dis* 2018; 19: 46–50 (in French).
- 44 Boşgelmez S, Aker T, Oznur AK, Ford JD. Assessment of lifetime history of exposure to traumatic stressors by incarcerated adults with the turkish version of the traumatic events screening instrument for adults (TESI-A): A pilot study. J Trauma Dissociation 2010; 11: 407–23.
- 45 Kaya N, Guler O, Cilli AS. Prevalence of psychiatric disorders among prisoners in Konya prison [in Turkish]. Anadolu Psikiyatri Dergisi 2004; 5: 85–91.

- 46 Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980-2013. Int J Epidemiol 2014; 43: 476–93.
- 47 Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
- 48 Mundt AP, Baranyi G, Gabrysch C, Fazel S. Substance use during imprisonment in low- and middle-income countries. *Epidemiol Rev* 2018; 40: 70–81.
- 49 Bennett T, Holloway K. The causal connection between drug misuse and crime. Br J Criminol 2009; 49: 513–31.
- 50 Walker J, Illingworth C, Canning A, et al. Changes in mental state associated with prison environments: a systematic review. *Acta Psychiatr Scand* 2014; 129: 427–36.
- 51 Baier A, Fritsch R, Ignatyev Y, Priebe S, Mundt AP. The course of major depression during imprisonment—a one year cohort study. J Affect Disord 2016; 189: 207–13.
- 52 Yoon IA, Slade K, Fazel S. Outcomes of psychological therapies for prisoners with mental health problems: a systematic review and meta-analysis. J Consult Clin Psychol 2017; 85: 783–802.
- 53 Hopkin G, Evans-Lacko S, Forrester A, Shaw J, Thornicroft G. Interventions at the transition from prison to community for prisoners with mental illness: a systematic review. *Adm Policy Ment Health* 2018; 45: 623–34.
- 54 Shidhaye R, Murhar V, Gangale S, et al. The effect of VISHRAM, a grass-roots community-based mental health programme, on the treatment gap for depression in rural communities in India: a population-based study. *Lancet Psychiatry* 2017; 4: 128–35.
- 55 Naslund JA, Aschbrenner KA, Araya R, et al. Digital technology for treating and preventing mental disorders in low-income and middle-income countries: a narrative review of the literature. *Lancet Psychiatry* 2017; 4: 486–500.
- 56 de Jesus MJ, Razzouk D, Thara R, Eaton J, Thornicroft G. Packages of care for schizophrenia in low- and middle-income countries. *PLoS Med* 2009; 6: e1000165.